{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,4,28]],"date-time":"2026-04-28T03:49:24Z","timestamp":1777348164391,"version":"3.51.4"},"reference-count":75,"publisher":"Elsevier BV","issue":"10","license":[{"start":{"date-parts":[[2018,12,1]],"date-time":"2018-12-01T00:00:00Z","timestamp":1543622400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"}],"content-domain":{"domain":["clinicalkey.jp","clinicalkey.com","clinicalkey.es","clinicalkey.com.au","clinicalkey.fr","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Transplantation Proceedings"],"published-print":{"date-parts":[[2018,12]]},"DOI":"10.1016\/j.transproceed.2018.05.014","type":"journal-article","created":{"date-parts":[[2018,5,29]],"date-time":"2018-05-29T16:42:10Z","timestamp":1527612130000},"page":"4015-4022","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":6,"title":["Cytomegalovirus Disease After Liver Transplant\u2014A Description of a Treatment-Resistant Case: A Case Report and Literature Review"],"prefix":"10.1016","volume":"50","author":[{"given":"P.","family":"Czarnecka","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"K.","family":"Czarnecka","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"O.","family":"Tronina","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"M.","family":"Durlik","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.transproceed.2018.05.014_bib1","doi-asserted-by":"crossref","first-page":"1439","DOI":"10.1086\/652438","article-title":"Cytomegalovirus seroprevalence in the United States: the national health and nutrition examination surveys, 1988-2004","volume":"50","author":"Bate","year":"2010","journal-title":"Clin Infect Dis"},{"key":"10.1016\/j.transproceed.2018.05.014_bib2","doi-asserted-by":"crossref","first-page":"260","DOI":"10.3947\/ic.2013.45.3.260","article-title":"Cytomegalovirus infections in solid organ transplantation: a review","volume":"45","author":"Ramanan","year":"2013","journal-title":"Infect Chemother"},{"key":"10.1016\/j.transproceed.2018.05.014_bib3","doi-asserted-by":"crossref","first-page":"202","DOI":"10.1002\/rmv.655","article-title":"Review of cytomegalovirus seroprevalence and demographic characteristics associated with infection","volume":"20","author":"Cannon","year":"2010","journal-title":"Rev Med Virol"},{"key":"10.1016\/j.transproceed.2018.05.014_bib4","doi-asserted-by":"crossref","first-page":"1143","DOI":"10.1086\/508173","article-title":"Seroprevalence of cytomegalovirus infection in the United States, 1988-1994","volume":"43","author":"Staras","year":"2006","journal-title":"Clin Infect Dis"},{"key":"10.1016\/j.transproceed.2018.05.014_bib5","doi-asserted-by":"crossref","first-page":"633","DOI":"10.1007\/s11908-012-0292-2","article-title":"Cytomegalovirus in solid organ transplantation: epidemiology, prevention, and treatment","volume":"14","author":"Beam","year":"2012","journal-title":"Curr Infect Dis Rep"},{"key":"10.1016\/j.transproceed.2018.05.014_bib6","doi-asserted-by":"crossref","first-page":"4849","DOI":"10.3748\/wjg.14.4849","article-title":"Cytomegalovirus infection after liver transplantation: current concepts and challenges","volume":"14","author":"Razonable","year":"2008","journal-title":"World J Gastroenterol"},{"key":"10.1016\/j.transproceed.2018.05.014_bib7","doi-asserted-by":"crossref","first-page":"61","DOI":"10.1146\/annurev.me.42.020191.000425","article-title":"Latency of the human herpesviruses","volume":"42","author":"Croen","year":"1991","journal-title":"Annu Rev Med"},{"key":"10.1016\/j.transproceed.2018.05.014_bib8","doi-asserted-by":"crossref","first-page":"144","DOI":"10.1592\/phco.30.2.144","article-title":"Defining the risks for cytomegalovirus infection and disease after solid organ transplantation","volume":"30","author":"Stratta","year":"2010","journal-title":"Pharmacotherapy"},{"key":"10.1016\/j.transproceed.2018.05.014_bib9","doi-asserted-by":"crossref","first-page":"24","DOI":"10.1111\/ajt.12006","article-title":"CMV: prevention, diagnosis and therapy","volume":"13","author":"Kotton","year":"2013","journal-title":"Am J Transplant"},{"key":"10.1016\/j.transproceed.2018.05.014_bib10","doi-asserted-by":"crossref","first-page":"2453","DOI":"10.1111\/j.1600-6143.2009.02824.x","article-title":"The \u201cindirect\u201d effects of cytomegalovirus infection","volume":"9","author":"Freeman","year":"2009","journal-title":"Am J Transplant"},{"key":"10.1016\/j.transproceed.2018.05.014_bib11","doi-asserted-by":"crossref","first-page":"893","DOI":"10.1002\/jmv.23539","article-title":"High risk of cytomegalovirus infection following solid organ transplantation despite prophylactic therapy","volume":"85","author":"Harvala","year":"2013","journal-title":"J\u00a0Med Virol"},{"key":"10.1016\/j.transproceed.2018.05.014_bib12","doi-asserted-by":"crossref","first-page":"S78","DOI":"10.1111\/j.1600-6143.2009.02897.x","article-title":"Cytomegalovirus in solid organ transplant recipients","volume":"9","author":"Humar","year":"2009","journal-title":"Am J Transplant"},{"key":"10.1016\/j.transproceed.2018.05.014_bib13","doi-asserted-by":"crossref","first-page":"333","DOI":"10.1097\/TP.0b013e31829df29d","article-title":"Updated international consensus guidelines on the management of cytomegalovirus in solid-organ transplantation","volume":"96","author":"Kotton","year":"2013","journal-title":"Transplantation"},{"key":"10.1016\/j.transproceed.2018.05.014_bib14","doi-asserted-by":"crossref","first-page":"10658","DOI":"10.3748\/wjg.v20.i31.10658","article-title":"Cytomegalovirus infection in liver transplant recipients: Updates on clinical management","volume":"20","author":"Marcelin","year":"2014","journal-title":"World J Gastroenterol"},{"key":"10.1016\/j.transproceed.2018.05.014_bib15","doi-asserted-by":"crossref","first-page":"118","DOI":"10.1053\/j.ajkd.2011.04.010","article-title":"Human cytomegalovirus and kidney transplantation: A clinician's update","volume":"58","author":"De Keyzer","year":"2011","journal-title":"Am J Kidney Dis"},{"key":"10.1016\/j.transproceed.2018.05.014_bib16","doi-asserted-by":"crossref","first-page":"521","DOI":"10.1016\/S0891-5520(05)70158-6","article-title":"Infectious complications of solid organ transplantations","volume":"15","author":"Simon","year":"2001","journal-title":"Infect Dis Clin North Am"},{"issue":"5 Pt 1","key":"10.1016\/j.transproceed.2018.05.014_bib17","first-page":"638","article-title":"Cytomegalovirus infection and survival in lung transplant recipients","volume":"10","author":"Duncan","year":"1991","journal-title":"J\u00a0Hear lung Transplant"},{"key":"10.1016\/j.transproceed.2018.05.014_bib18","doi-asserted-by":"crossref","first-page":"529","DOI":"10.1016\/j.transproceed.2012.01.051","article-title":"Bortezomib is effective to treat acute humoral rejection after liver transplantation","volume":"44","author":"Lee","year":"2012","journal-title":"Transplant Proc"},{"key":"10.1016\/j.transproceed.2018.05.014_bib19","doi-asserted-by":"crossref","first-page":"2526","DOI":"10.1111\/j.1600-6143.2012.04126.x","article-title":"Bortezomib for acute antibody-mediated rejection in liver transplantation","volume":"12","author":"Paterno","year":"2012","journal-title":"Am J Transplant"},{"key":"10.1016\/j.transproceed.2018.05.014_bib20","doi-asserted-by":"crossref","first-page":"357","DOI":"10.1002\/lt.22233","article-title":"Liver allograft antibody-mediated rejection with demonstration of sinusoidal C4d staining and circulating donor-specific antibodies","volume":"17","author":"Kozlowski","year":"2011","journal-title":"Liver Transpl"},{"key":"10.1016\/j.transproceed.2018.05.014_bib21","doi-asserted-by":"crossref","first-page":"37","DOI":"10.1111\/j.1399-0012.1989.tb00531.x","article-title":"Evidence for hyperacute rejection of human liver grafts: The case of the canary kidneys","volume":"3","author":"Starzl","year":"1989","journal-title":"Clin Transplant"},{"key":"10.1016\/j.transproceed.2018.05.014_bib22","doi-asserted-by":"crossref","first-page":"1244","DOI":"10.1002\/lt.23948","article-title":"Acute liver allograft antibody-mediated rejection: An inter-institutional study of significant histopathological features","volume":"20","author":"O'Leary","year":"2014","journal-title":"Liver Transpl"},{"issue":"December 2003","key":"10.1016\/j.transproceed.2018.05.014_bib23","doi-asserted-by":"crossref","first-page":"1033","DOI":"10.1111\/j.1600-6143.2004.00500.x","article-title":"National conference to assess antibody-mediated rejection in solid organ transplantation","volume":"4","author":"Takemoto","year":"2004","journal-title":"Am J Transplant"},{"key":"10.1016\/j.transproceed.2018.05.014_bib24","doi-asserted-by":"crossref","first-page":"514","DOI":"10.1002\/lt.23826","article-title":"Antibody-mediated rejection in liver transplantation: current controversies and future directions","volume":"20","author":"Taner","year":"2014","journal-title":"Liver Transpl"},{"key":"10.1016\/j.transproceed.2018.05.014_bib25","doi-asserted-by":"crossref","first-page":"850","DOI":"10.1016\/j.transproceed.2004.12.228","article-title":"Does mycophenolate mofetil increase the incidence of cytomegalovirus disease compared with azathioprine after cadaveric kidney transplantation?","volume":"37","author":"Basic-Jukic","year":"2018","journal-title":"Transplant Proc"},{"key":"10.1016\/j.transproceed.2018.05.014_bib26","doi-asserted-by":"crossref","first-page":"1751","DOI":"10.1016\/j.transproceed.2005.03.072","article-title":"The influence of mycophenolate mofetil versus azathioprine and mycophenolic acid pharmacokinetics on the incidence of acute rejection and infectious complications after renal transplantation","volume":"37","author":"Satoh","year":"2018","journal-title":"Transplant Proc"},{"key":"10.1016\/j.transproceed.2018.05.014_bib27","doi-asserted-by":"crossref","first-page":"174","DOI":"10.1111\/j.1399-3062.2003.00032.x","article-title":"Low incidence of cytomegalovirus disease in liver transplant recipients receiving sirolimus primary immunosuppression with 3-day corticosteroid taper","volume":"5","author":"Trotter","year":"2003","journal-title":"Transpl Infect Dis"},{"key":"10.1016\/j.transproceed.2018.05.014_bib28","doi-asserted-by":"crossref","first-page":"490","DOI":"10.1182\/blood-2007-01-069294","article-title":"Sirolimus-based graft-versus-host disease prophylaxis protects against cytomegalovirus reactivation after allogeneic hematopoietic stem cell transplantation: A cohort analysis","volume":"110","author":"Marty","year":"2007","journal-title":"Blood"},{"key":"10.1016\/j.transproceed.2018.05.014_bib29","doi-asserted-by":"crossref","first-page":"2453","DOI":"10.1111\/j.1600-6143.2011.03674.x","article-title":"Cytomegalovirus incidence between everolimus versus mycophenolate in de novo renal transplants: pooled analysis of three clinical trials","volume":"11","author":"Brennan","year":"2011","journal-title":"Am J Transplant"},{"issue":"7","key":"10.1016\/j.transproceed.2018.05.014_bib30","doi-asserted-by":"crossref","first-page":"e78","DOI":"10.1111\/j.1432-2277.2012.01489.x","article-title":"Successful outcome of ganciclovir-resistant cytomegalovirus infection in organ transplant recipients after conversion to mTOR inhibitors","volume":"25","author":"Sab\u00e9","year":"2012","journal-title":"Transpl Int"},{"issue":"8 Suppl. 1","key":"10.1016\/j.transproceed.2018.05.014_bib31","doi-asserted-by":"crossref","first-page":"S7","DOI":"10.1093\/ajhp\/62.suppl_1.S7","article-title":"Epidemiology of cytomegalovirus disease in solid organ and hematopoietic stem cell transplant recipients","volume":"62","author":"Razonable","year":"2005","journal-title":"Am J Health Syst Pharm"},{"key":"10.1016\/j.transproceed.2018.05.014_bib32","doi-asserted-by":"crossref","first-page":"149","DOI":"10.1111\/j.1399-0012.2006.00618.x","article-title":"Cytomegalovirus in transplantation - challenging the status quo","volume":"21","author":"Fishman","year":"2007","journal-title":"Clin Transplant"},{"key":"10.1016\/j.transproceed.2018.05.014_bib33","doi-asserted-by":"crossref","first-page":"370","DOI":"10.4254\/wjh.v6.i6.370","article-title":"Management of cytomegalovirus infection and disease in liver transplant recipients","volume":"6","author":"Bruminhent","year":"2014","journal-title":"World J Hepatol"},{"key":"10.1016\/j.transproceed.2018.05.014_bib34","doi-asserted-by":"crossref","first-page":"207","DOI":"10.1016\/S0973-6883(11)60236-3","article-title":"Atypical presentation of cytomegalovirus infection in a liver transplant patient","volume":"1","author":"Bansal","year":"2011","journal-title":"J\u00a0Clin Exp Hepatol"},{"key":"10.1016\/j.transproceed.2018.05.014_bib35","doi-asserted-by":"crossref","first-page":"850","DOI":"10.1034\/j.1600-6143.2002.20907.x","article-title":"The impact of cytomegalovirus infection and disease on rejection episodes in renal allograft recipients","volume":"2","author":"Sagedal","year":"2002","journal-title":"Am J Transplant"},{"key":"10.1016\/j.transproceed.2018.05.014_bib36","doi-asserted-by":"crossref","first-page":"577","DOI":"10.1016\/j.coi.2007.07.012","article-title":"Acceleration of allograft failure by cytomegalovirus","volume":"19","author":"Streblow","year":"2007","journal-title":"Curr Opin Immunol"},{"key":"10.1016\/j.transproceed.2018.05.014_bib37","doi-asserted-by":"crossref","first-page":"468","DOI":"10.1093\/clinids\/23.3.468","article-title":"Exposure to cytomegalovirus from the donated organ is a risk factor for bacteremia in orthotopic liver transplant recipients","volume":"23","author":"Falagas","year":"1996","journal-title":"Clin Infect Dis"},{"issue":"2","key":"10.1016\/j.transproceed.2018.05.014_bib38","doi-asserted-by":"crossref","first-page":"106","DOI":"10.1016\/S0002-9343(97)80021-6","article-title":"The independent role of cytomegalovirus as a risk factor for invasive fungal disease in orthotopic liver transplant recipients","volume":"103","author":"George","year":"1997","journal-title":"Am J Med"},{"key":"10.1016\/j.transproceed.2018.05.014_bib39","doi-asserted-by":"crossref","first-page":"1346","DOI":"10.1093\/clinids\/20.5.1346","article-title":"Pretransplantation assessment of the risk of lymphoproliferative disorder","volume":"20","author":"Walker","year":"1995","journal-title":"Clin Infect Dis"},{"key":"10.1016\/j.transproceed.2018.05.014_bib40","doi-asserted-by":"crossref","first-page":"146","DOI":"10.1002\/lt.20566","article-title":"Hepatic artery thrombosis following orthotopic liver transplantation: a 10-year experience from a single centre in the United Kingdom","volume":"12","author":"Silva","year":"2006","journal-title":"Liver Transpl"},{"key":"10.1016\/j.transproceed.2018.05.014_bib41","doi-asserted-by":"crossref","first-page":"605","DOI":"10.1053\/jlts.2003.50057","article-title":"Late hepatic artery thrombosis after orthotopic liver transplantation","volume":"9","author":"Gunsar","year":"2003","journal-title":"Liver Transpl"},{"key":"10.1016\/j.transproceed.2018.05.014_bib42","doi-asserted-by":"crossref","first-page":"1138","DOI":"10.1053\/jlts.2002.36732","article-title":"CMV hepatitis after liver transplantation: incidence, clinical course, and long-term follow-up","volume":"8","author":"Seehofer","year":"2002","journal-title":"Liver Transpl"},{"key":"10.1016\/j.transproceed.2018.05.014_bib43","doi-asserted-by":"crossref","first-page":"1487","DOI":"10.1097\/01.TP.0000088668.28950.7C","article-title":"Progression of liver fibrosis in patients with chronic hepatitis C after orthotopic liver transplantation","volume":"76","author":"Chopra","year":"2003","journal-title":"Transplantation"},{"key":"10.1016\/j.transproceed.2018.05.014_bib44","doi-asserted-by":"crossref","first-page":"50","DOI":"10.1016\/j.jcv.2013.01.013","article-title":"Prospective study on CMV-reactivations under preemptive strategy in CMV-seropositive adult liver transplant recipients","volume":"57","author":"Lautenschlager","year":"2013","journal-title":"J\u00a0Clin Virol"},{"key":"10.1016\/j.transproceed.2018.05.014_bib45","doi-asserted-by":"crossref","first-page":"1093","DOI":"10.1002\/lt.23460","article-title":"Prophylaxis versus preemptive therapy for cytomegalovirus disease in high-risk liver transplant recipients","volume":"18","author":"Bodro","year":"2012","journal-title":"Liver Transpl"},{"key":"10.1016\/j.transproceed.2018.05.014_bib46","doi-asserted-by":"crossref","first-page":"515","DOI":"10.6061\/clinics\/2015(07)09","article-title":"Cytomegalovirus infection in transplant recipients","volume":"70","author":"Azevedo","year":"2015","journal-title":"Clinics (Sao Paulo)"},{"key":"10.1016\/j.transproceed.2018.05.014_bib47","doi-asserted-by":"crossref","first-page":"208","DOI":"10.1016\/j.jcv.2011.12.019","article-title":"Incidence of cytomegalovirus UL97 and UL54 amino acid substitutions detected after 100 or 200 days of valganciclovir prophylaxis","volume":"53","author":"Boivin","year":"2012","journal-title":"J\u00a0Clin Virol"},{"key":"10.1016\/j.transproceed.2018.05.014_bib48","doi-asserted-by":"crossref","first-page":"1228","DOI":"10.1111\/j.1600-6143.2010.03074.x","article-title":"The efficacy and safety of 200 days valganciclovir cytomegalovirus prophylaxis in high-risk kidney transplant recipients","volume":"10","author":"Humar","year":"2010","journal-title":"Am J Transplant"},{"key":"10.1016\/j.transproceed.2018.05.014_bib49","doi-asserted-by":"crossref","first-page":"1427","DOI":"10.1097\/TP.0b013e3181ff1493","article-title":"Extended valganciclovir prophylaxis in D+\/R- kidney transplant recipients is associated with long-term reduction in cytomegalovirus disease: Two-year results of the impact study","volume":"90","author":"Humar","year":"2010","journal-title":"Transplantation"},{"key":"10.1016\/j.transproceed.2018.05.014_bib50","doi-asserted-by":"crossref","first-page":"e74","DOI":"10.1097\/TP.0000000000001418","article-title":"Outcomes in transplant recipients treated with foscarnet for ganciclovir-resistant or refractory cytomegalovirus infection","volume":"100","author":"Avery","year":"2016","journal-title":"Transplantation"},{"key":"10.1016\/j.transproceed.2018.05.014_bib51","doi-asserted-by":"crossref","first-page":"313","DOI":"10.1093\/cid\/ciq143","article-title":"Effectiveness of valganciclovir 900 mg versus 450 mg for cytomegalovirus prophylaxis in transplantation: direct and indirect treatment comparison meta-analysis","volume":"52","author":"Kalil","year":"2011","journal-title":"Clin Infect Dis"},{"key":"10.1016\/j.transproceed.2018.05.014_bib52","doi-asserted-by":"crossref","first-page":"158","DOI":"10.1111\/j.1600-6143.2007.02026.x","article-title":"A\u00a0survey of CMV prevention strategies after liver transplantation","volume":"8","author":"Levitsky","year":"2008","journal-title":"Am J Transplant"},{"key":"10.1016\/j.transproceed.2018.05.014_bib53","doi-asserted-by":"crossref","first-page":"2457","DOI":"10.1111\/j.1600-6143.2012.04087.x","article-title":"Cytomegalovirus replication kinetics in solid organ transplant recipients managed by preemptive therapy","volume":"12","author":"Atabani","year":"2012","journal-title":"Am J Transplant"},{"key":"10.1016\/j.transproceed.2018.05.014_bib54","doi-asserted-by":"crossref","first-page":"1063","DOI":"10.1097\/TP.0b013e31822fa4b7","article-title":"Clinical utility of molecular surveillance for cytomegalovirus after antiviral prophylaxis in high-risk solid organ transplant recipients","volume":"92","author":"Lisboa","year":"2011","journal-title":"Transplantation"},{"key":"10.1016\/j.transproceed.2018.05.014_bib55","doi-asserted-by":"crossref","first-page":"2189","DOI":"10.1016\/j.transproceed.2009.06.005","article-title":"Prophylactic therapy with valgancyclovir in high-risk (cytomegalovirus D+\/R\u2212) liver transplant recipients: a single-center experience","volume":"41","author":"Montejo","year":"2009","journal-title":"Transplant Proc"},{"key":"10.1016\/j.transproceed.2018.05.014_bib56","doi-asserted-by":"crossref","first-page":"251","DOI":"10.1097\/TP.0b013e318200b9f0","article-title":"Impact of a preemptive strategy after 3 months of valganciclovir cytomegalovirus prophylaxis in kidney transplant recipients","volume":"91","author":"Boillat Blanco","year":"2011","journal-title":"Transplantation"},{"key":"10.1016\/j.transproceed.2018.05.014_bib57","doi-asserted-by":"crossref","first-page":"320","DOI":"10.1097\/TP.0b013e3181bc0301","article-title":"Preemptive versus sequential prophylactic-preemptive treatment regimens for\u00a0cytomegalovirus in renal transplantation: Comparison of treatment failure and antiviral resistance","volume":"89","author":"Van Der Beek","year":"2010","journal-title":"Transplantation"},{"key":"10.1016\/j.transproceed.2018.05.014_bib58","first-page":"186","article-title":"Comparison of two molecular assays for detection of cytomegalovirus DNA in whole blood and plasma samples from transplant recipients","volume":"39","author":"Costa","year":"2016","journal-title":"New Microbiol"},{"key":"10.1016\/j.transproceed.2018.05.014_bib59","doi-asserted-by":"crossref","first-page":"968","DOI":"10.1097\/00007890-200203270-00025","article-title":"The clinical use of various blood compartments for cytomegalovirus (CMV) DNA quantitation in transplant recipients with CMV disease","volume":"73","author":"Razonable","year":"2002","journal-title":"Transplantation"},{"key":"10.1016\/j.transproceed.2018.05.014_bib60","doi-asserted-by":"crossref","first-page":"258","DOI":"10.1111\/j.1600-6143.2008.02513.x","article-title":"Interlaboratory comparison of cytomegalovirus viral load assays","volume":"9","author":"Pang","year":"2009","journal-title":"Am J Transplant"},{"key":"10.1016\/j.transproceed.2018.05.014_bib61","doi-asserted-by":"crossref","first-page":"13","DOI":"10.1016\/j.jcv.2012.09.017","article-title":"Determination, validation, and standardization of a CMV DNA cut-off value in plasma for preemptive treatment of CMV infection in solid organ transplant recipients at lower risk for CMV infection","volume":"56","author":"Mart\u00edn-Gandul","year":"2013","journal-title":"J\u00a0Clin Virol"},{"issue":"July","key":"10.1016\/j.transproceed.2018.05.014_bib62","doi-asserted-by":"crossref","first-page":"829","DOI":"10.1086\/342601","article-title":"Cytomegalovirus (CMV) virus load kinetics to predict recurrent disease in solid-organ transplant patients with CMV disease","volume":"186","author":"Humar","year":"2002","journal-title":"J\u00a0Infect Dis"},{"key":"10.1016\/j.transproceed.2018.05.014_bib63","doi-asserted-by":"crossref","first-page":"2106","DOI":"10.1111\/j.1600-6143.2007.01910.x","article-title":"Oral valganciclovir is noninferior to intravenous ganciclovir for the treatment of cytomegalovirus disease in solid organ transplant recipients","volume":"7","author":"\u00c5sberg","year":"2007","journal-title":"Am J Transplant"},{"key":"10.1016\/j.transproceed.2018.05.014_bib64","doi-asserted-by":"crossref","first-page":"1205","DOI":"10.1111\/j.1600-6143.2009.02617.x","article-title":"Long-term outcomes of CMV disease treatment with valganciclovir versus IV ganciclovir in solid organ transplant recipients","volume":"9","author":"\u00c5sberg","year":"2009","journal-title":"Am J Transplant"},{"key":"10.1016\/j.transproceed.2018.05.014_bib65","doi-asserted-by":"crossref","first-page":"1546","DOI":"10.1093\/cid\/cit096","article-title":"Virologic suppression measured by a cytomegalovirus (CMV) DNA test calibrated to the world health organization international standard is predictive of CMV disease resolution in transplant recipients","volume":"56","author":"Razonable","year":"2013","journal-title":"Clin Infect Dis"},{"key":"10.1016\/j.transproceed.2018.05.014_bib66","doi-asserted-by":"crossref","first-page":"697","DOI":"10.1177\/135965350901400512","article-title":"Cytomegalovirus resistance in solid organ transplant recipients treated with intravenous ganciclovir or oral valganciclovir","volume":"14","author":"Boivin","year":"2009","journal-title":"Antivir Ther"},{"key":"10.1016\/j.transproceed.2018.05.014_bib67","doi-asserted-by":"crossref","first-page":"1018","DOI":"10.1093\/cid\/cis1035","article-title":"Clinical aspects of cytomegalovirus antiviral resistance in solid organ transplant recipients","volume":"56","author":"Le Page","year":"2013","journal-title":"Clin Infect Dis"},{"key":"10.1016\/j.transproceed.2018.05.014_bib68","doi-asserted-by":"crossref","first-page":"689","DOI":"10.1128\/CMR.00009-10","article-title":"Antiviral drug resistance of human cytomegalovirus","volume":"23","author":"Lurain","year":"2010","journal-title":"Clin Microbiol Rev"},{"key":"10.1016\/j.transproceed.2018.05.014_bib69","doi-asserted-by":"crossref","DOI":"10.1002\/14651858.CD005133.pub3","article-title":"Pre-emptive treatment for cytomegalovirus viraemia to prevent cytomegalovirus disease in solid organ transplant recipients","author":"Owers","year":"2013","journal-title":"Cochrane Database Syst Rev"},{"issue":"Suppl. 4","key":"10.1016\/j.transproceed.2018.05.014_bib70","doi-asserted-by":"crossref","first-page":"93","DOI":"10.1111\/ajt.12103","article-title":"Cytomegalovirus in solid organ transplantation","volume":"13","author":"Razonable","year":"2013","journal-title":"Am J Transplant"},{"key":"10.1016\/j.transproceed.2018.05.014_bib71","doi-asserted-by":"crossref","first-page":"318","DOI":"10.1016\/j.antiviral.2009.10.004","article-title":"A\u00a0new tool linking human cytomegalovirus drug resistance mutations to resistance phenotypes","volume":"85","author":"Chevillotte","year":"2010","journal-title":"Antiviral Res"},{"key":"10.1016\/j.transproceed.2018.05.014_bib72","doi-asserted-by":"crossref","first-page":"318","DOI":"10.1093\/ofid\/ofx143","article-title":"Comparison of standardized cytomegalovirus (CMV) viral load thresholds in whole blood and plasma of solid organ and hematopoietic stem cell transplant recipients with CMV infection and disease","volume":"4","author":"Dioverti","year":"2017","journal-title":"Open Forum Infect Dis"},{"key":"10.1016\/j.transproceed.2018.05.014_bib73","doi-asserted-by":"crossref","first-page":"117","DOI":"10.2217\/imt.09.82","article-title":"Immune-based therapies for cytomegalovirus infection","volume":"2","author":"Razonable","year":"2010","journal-title":"Immunotherapy"},{"key":"10.1016\/j.transproceed.2018.05.014_bib74","doi-asserted-by":"crossref","first-page":"256","DOI":"10.1007\/s40506-014-0021-5","article-title":"Cytomegalovirus Treatment","volume":"6","author":"Tan","year":"2014","journal-title":"Curr Treat Options Infect Dis"},{"key":"10.1016\/j.transproceed.2018.05.014_bib75","doi-asserted-by":"crossref","first-page":"390","DOI":"10.1111\/tid.12537","article-title":"Ganciclovir-resistant cytomegalovirus infection in solid organ transplant recipients: a single-center retrospective cohort study","volume":"18","author":"Young","year":"2016","journal-title":"Transpl Infect Dis"}],"container-title":["Transplantation Proceedings"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S004113451830719X?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S004113451830719X?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,7,4]],"date-time":"2025-07-04T20:45:10Z","timestamp":1751661910000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S004113451830719X"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2018,12]]},"references-count":75,"journal-issue":{"issue":"10","published-print":{"date-parts":[[2018,12]]}},"alternative-id":["S004113451830719X"],"URL":"https:\/\/doi.org\/10.1016\/j.transproceed.2018.05.014","relation":{},"ISSN":["0041-1345"],"issn-type":[{"value":"0041-1345","type":"print"}],"subject":[],"published":{"date-parts":[[2018,12]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Cytomegalovirus Disease After Liver Transplant\u2014A Description of a Treatment-Resistant Case: A Case Report and Literature Review","name":"articletitle","label":"Article Title"},{"value":"Transplantation Proceedings","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.transproceed.2018.05.014","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2018 Elsevier Inc. All rights reserved.","name":"copyright","label":"Copyright"}]}}